Electrical Impedance Tomography-Guided Precision Nursing in an Older Patient With Septic Shock and ARDS: A Case Report.

Nurs Crit CareSep 26, 2026
Case ReportGeriatricsPulmonologyEmergency Medicine

Susu Lin, Wenchao Mao, Jiaping Zhao et al.

✦ AI-curated · Sources linked

Case in brief

A 79-year-old patient with septic shock, ARDS, and MODS underwent precision nursing management utilizing electrical impedance tomography (EIT). The approach included EIT-guided PEEP titration, continuous monitoring during CRRT, and optimal positioning for ventilation. After 10 days, the patient's PaO2/FiO2 ratio improved from 150 to 356 mmHg, leading to successful extubation.

Diagnostic / clinical pearl

EIT can effectively guide fluid management and ventilation strategies in critically ill patients, balancing the need for aggressive resuscitation with lung protection.

Why it matters

This case highlights the potential of EIT in complex critical care settings, providing a structured approach to manage competing therapeutic goals in patients with septic shock and ARDS.

Source

PubMed · PMID 42786762

Published in Nurs Crit Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.